大血管闭塞性卒中机械取栓前替奈普酶与阿替普酶股动脉穿刺点并发症比较
本研究比较了大血管闭塞性卒中患者机械取栓前使用替奈普酶与阿替普酶的股动脉穿刺点并发症发生率。139例患者中46例(33.1%)接受替奈普酶、93例(66.9%)接受阿替普酶,两组腹股沟血肿、穿刺点渗血需手动压迫及需手术的动脉闭塞发生率均相似(P无显著差异),未见夹层、动静脉瘘或腹膜后血肿。
要点
- 替奈普酶组与阿替普酶组股动脉穿刺点并发症发生率相似(P无显著差异)。
- 所有病例均置入8F鞘且未用超声引导,血管闭合采用Angio-Seal。
- 未见夹层、动静脉瘘或腹膜后血肿。
核心结论
- 大血管闭塞性卒中机械取栓前使用替奈普酶与阿替普酶相比,股动脉穿刺点并发症发生率无改变。
研究设计与样本
- 回顾性分析2020年1月至2022年8月所有机械取栓前接受静脉溶栓的大血管闭塞性卒中患者;2021年5月本医疗系统将卒中溶栓药物由阿替普酶改为替奈普酶,从而比较两组股动脉穿刺点并发症;共139例,替奈普酶组46/139(33.1%)、阿替普酶组93/139(66.9%)。
关键影像表现/征象
- 保守处理的腹股沟血肿:替奈普酶组2.2% vs 阿替普酶组4.3%。
- 需手动压迫的穿刺点延迟渗血:替奈普酶组6.5% vs 阿替普酶组2.2%。
- 需手术的动脉闭塞:替奈普酶组2.2% vs 阿替普酶组1.1%。
- 未见夹层、动静脉瘘或腹膜后血肿。
诊断标准与关键数值
- 主要穿刺点并发症定义为需手术处理,次要定义为保守处理。
- 上述各项并发症发生率在替奈普酶组与阿替普酶组间差异均无统计学意义(P无显著差异)。
临床应用与阅片要点
- 所有病例均置入8F鞘且未用超声引导,血管闭合采用Angio-Seal。
- 两组基线人口学、合并抗栓药物及围手术期凝血实验室检查结果相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: IV thrombolysis with alteplase before mechanical thrombectomy for emergent large-vessel-occlusion stroke is associated with access-site bleeding complications. However, the incidence of femoral access-site complications with tenecteplase before mechanical thrombectomy requires exploration. Here, femoral access-site complications with tenecteplase versus alteplase before mechanical thrombectomy for large-vessel-occlusion stroke were compared.
MATERIALS AND METHODS: All patients receiving IV thrombolytics before mechanical thrombectomy for large-vessel-occlusion stroke who presented from January 2020 to August 2022 were reviewed. In May 2021, our health care system switched from alteplase to tenecteplase as the primary thrombolytic for all patients with stroke, facilitating the comparison of alteplase-versus-tenecteplase femoral access-site complication rates. Major (requiring surgery) and minor (managed conservatively) access-site complications were assessed.
RESULTS: One hundred thirty-nine patients underwent transfemoral mechanical thrombectomy for large-vessel-occlusion stroke, of whom 46/139 (33.1%) received tenecteplase and 93/139 (66.9%) received alteplase. In all cases (n = 139), an 8F sheath was inserted without sonographic guidance, and vascular closure was obtained with an Angio-Seal. Baseline demographics, concomitant antithrombotic medications, and periprocedural coagulation lab findings were similar between groups. The incidence of conservatively managed groin hematomas (2.2% versus 4.3%), delayed access-site oozing requiring manual compression (6.5% versus 2.2%), and arterial occlusion requiring surgery (2.2% versus 1.1%) was similar between the tenecteplase and alteplase groups, respectively (P = not significant). No dissection, arteriovenous fistula, or retroperitoneal hematoma was observed.
CONCLUSIONS: Tenecteplase compared with alteplase before mechanical thrombectomy for large-vessel-occlusion stroke is not associated with an alteration in femoral access-site complication rates.
引用
- Hendrix, Collins, Goren, et al. Femoral Access-Site Complications with Tenecteplase versus Alteplase before Mechanical Thrombectomy for Large-Vessel-Occlusion Stroke. AJNR Am J Neuroradiol. 2023. PMID: 37169538. doi:10.3174/ajnr.A7862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。